Clinical use and the Italian demand for activated prothrombin complex and activated recombinant factor VII concentrates.
作者信息
Coppola Antonio, Tagliaferri Annarita, Calizzani Gabriele, Candura Fabio, Franchini Massimo, Ruosi Carlo, Grazzini Giuliano, Di Minno Giovanni
机构信息
Regional Reference Centre for Coagulation Disorders, Federico II University Hospital, Naples, Italy.
Regional Reference Centre for Inherited Bleeding Disorders, University Hospital, Parma, Italy.
出版信息
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s101-9. doi: 10.2450/2013.016s.
Abstract
摘要
相似文献
1
Clinical use and the Italian demand for activated prothrombin complex and activated recombinant factor VII concentrates.
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s101-9. doi: 10.2450/2013.016s.
2
Clinical efficacy of prothrombin complex concentrates and recombinant factor VIIa in the treatment of bleeding episodes in patients with factor VII and IX inhibitors.
Thromb Res. 1999 Aug 15;95(4 Suppl 1):S31-8. doi: 10.1016/s0049-3848(99)00082-1.
3
Use of prothrombin complex concentrates in anticoagulation.
Am J Hematol. 2008 Apr;83(4):344-5. doi: 10.1002/ajh.21142.
4
A reappraisal of plasma, prothrombin complex concentrates, and recombinant factor VIIa in patient blood management.
Crit Care Clin. 2012 Jul;28(3):413-26, vi-vii. doi: 10.1016/j.ccc.2012.04.002.
5
Activated prothrombin complex concentrates and recombinant factor VIIa in the bleeding patient: are they appropriate and safe?
J Thorac Cardiovasc Surg. 2003 Dec;126(6):2112-3. doi: 10.1016/j.jtcvs.2003.06.004.
6
Hemostatic agents for bleeding: recombinant-activated factor VII and beyond.
Semin Thromb Hemost. 2015 Apr;41(3):342-7. doi: 10.1055/s-0034-1381234. Epub 2014 Jun 17.
7
Clinical use and the Italian demand for prothrombin complex concentrates.
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s94-100. doi: 10.2450/2013.015s.
8
Adjunctive role for recombinant activated factor VII in the treatment of bleeding secondary to a factor V inhibitor.
Blood Coagul Fibrinolysis. 2008 Jun;19(4):327-8. doi: 10.1097/MBC.0b013e3283001d49.
9
The latest in trauma nursing.
Nurs Manage. 2003;34 Suppl Critical:19.
10
Prophylaxis in congenital coagulation disorders: past, present and future.
Blood Transfus. 2008 Sep;6 Suppl 2(Suppl 2):s1-3. doi: 10.2450/2008.0029-08.
引用本文的文献
1
Uncovered needs in the management of inherited bleeding disorders in Italy.
Blood Transfus. 2014 Apr;12 Suppl 3(Suppl 3):s563-6. doi: 10.2450/2014.0036-14s.
2
Plasma-derived medicinal products: demand and clinical use.
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s2-5. doi: 10.2450/2013.002s.
3
Public expenditure for plasma-derived and recombinant medicinal products in Italy.
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s110-7. doi: 10.2450/2013.017s.
本文引用的文献
1
Plasma-derived medicinal products in Italy: information sources and flows.
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s13-7. doi: 10.2450/2013.004s.
2
Challenges in the management of hemophilia B with inhibitor.
Semin Thromb Hemost. 2013 Oct;39(7):767-71. doi: 10.1055/s-0033-1356574. Epub 2013 Sep 10.
3
FEIBA versus NovoSeven in hemophilia patients with inhibitors.
Semin Thromb Hemost. 2013 Oct;39(7):772-8. doi: 10.1055/s-0033-1354425. Epub 2013 Sep 8.
4
Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER).
Haematologica. 2013 Apr;98(4):538-44. doi: 10.3324/haematol.2012.074039. Epub 2013 Feb 12.
5
SURgical interventions with FEIBA (SURF): international registry of surgery in haemophilia patients with inhibitory antibodies.
Haemophilia. 2013 May;19(3):e143-50. doi: 10.1111/hae.12080. Epub 2013 Jan 3.
6
Replacement therapy for bleeding episodes in factor VII deficiency. A prospective evaluation.
Thromb Haemost. 2013 Feb;109(2):238-47. doi: 10.1160/TH12-07-0476. Epub 2012 Dec 13.
7
Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.
Br J Haematol. 2013 Jan;160(2):153-70. doi: 10.1111/bjh.12091. Epub 2012 Nov 15.
8
Consensus recommendations for the use of FEIBA(®) in haemophilia A patients with inhibitors undergoing elective orthopaedic and non-orthopaedic surgery.
Haemophilia. 2013 Mar;19(2):294-303. doi: 10.1111/hae.12028. Epub 2012 Sep 19.
9
Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity.
J Thromb Haemost. 2012 Sep;10(9):1938-43. doi: 10.1111/j.1538-7836.2012.04844.x.
10
Acquired inhibitors of coagulation factors: part I-acquired hemophilia A.
Semin Thromb Hemost. 2012 Jul;38(5):433-46. doi: 10.1055/s-0032-1315757. Epub 2012 Jun 27.
Zotero 插件